No Data
No Data
US FDA Approves Hengrui Medicine's Abbreviated New Drug Application for Anti-Cancer Injection
Jiangsu Hengrui Pharmaceuticals (600276.SH) Class 1 new drug SHR2554 tablet declared for listing, treating relapsed and refractory peripheral T-cell lymphoma.
On October 11, the China National Medical Products Administration Drug Evaluation Center (CDE) official website has just announced that jiangsu hengrui pharmaceuticals (600276.SH) has submitted an application for the listing of the class 1 new drug SHR2554 tablets and has been accepted.
Jiangsu Hengrui Pharmaceuticals (600276.SH): Injection paclitaxel (albumin bound) has obtained the approval number from the USA FDA.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company received a notification from the US Food and Drug Administration (FDA).
Hengrui Medicine Gets Green Light to Trial Bacterial Infection Drug
Jiangsu Hengrui Pharmaceuticals (600276.SH): Injection HRS-2183 obtained the drug clinical trial approval notice.
格隆汇October 9th | jiangsu hengrui pharmaceuticals (600276.SH) announced that it has received the approval and issuance of the "Drug Clinical Trial Approval Notice" for injection HRS-2183 from the National Medical Products Administration and will conduct clinical trials in the near future. Injection HRS-2183 is intended for the treatment of bacterial infections. According to the investigation, there are currently no similar products approved for marketing domestically and internationally. As of now, the cumulative research and development expenses for the injection HRS-2183 project have reached approximately 19.35 million yuan.
Jiangsu Hengrui Pharmaceuticals (600276.SH) has accumulated repurchased 4.5561 million shares, spending 0.187 billion yuan.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that, as of September 30, 2024, the company conducted trading through centralized competitive bidding...
No Data
No Data